<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554200</url>
  </required_header>
  <id_info>
    <org_study_id>15-156</org_study_id>
    <secondary_id>2017-002695-45</secondary_id>
    <nct_id>NCT03554200</nct_id>
  </id_info>
  <brief_title>EMPA Acute Heart Failure</brief_title>
  <official_title>Effect of Empagliflozin on Cardiac Output in Patients With Acute Heart Failure (EMPA Acute Heart Failure)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators are aiming to treat patients with acute heart failure with or&#xD;
      without diabetes with Empagliflozin or placebo. Given the beneficial effects of Empagliflozin&#xD;
      on heart failure hospitalization in the EMPA-REG OUTCOME trial, the investigators do expect a&#xD;
      similar beneficial effect to be present in patients with acute heart failure. Acute heart&#xD;
      failure is a state of hydropic decompensation resulting in dyspnea and congestions, caused by&#xD;
      different etiologies of cardiac disease. Recompensation is reached by application of diuretic&#xD;
      drugs and fluid restriction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study patients will be randomized into 2 groups (standard of care +&#xD;
      Empagliflozin 10 mg/d or standard of care + placebo). Cardiac output will be assessed by a&#xD;
      medical device for noninvasive monitoring of hemodynamic parameters (cardiac output, systemic&#xD;
      vascular resistance, stroke volume and blood pressure) using finger cuff technology for pulse&#xD;
      contour analysis.&#xD;
&#xD;
      These investigations will inform about Empagliflozin dependent effects on hemodynamic and&#xD;
      cardiac function in patients with acute heart failure. The investigation will further assess&#xD;
      the therapeutic efficacy of Empagliflozin on heart failure symptoms using objective&#xD;
      (respiratory rate, oxygen requirement, peak expiratory flow rate, urinary volume, body&#xD;
      weight, diuretic requirement, length of hospital stay) and well accepted, patient orientated&#xD;
      secondary endpoints. In addition, metabolic regulators and parameters relevant for cardiac&#xD;
      function and substrate metabolism will be assessed to further investigate possible mechanisms&#xD;
      of Empagliflozin-dependent actions on cardiac function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID 19&#xD;
  </why_stopped>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Actual">October 29, 2020</completion_date>
  <primary_completion_date type="Actual">October 29, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single center, prospective, placebo-controlled, double blind, randomized, 2-arm parallel, interventional, exploratory pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This trial is double-blinded. After randomization neither the patients nor the investigator will be aware of the treatment allocation. Patients assigned to one of the double-blinded treatment will take one tablet Empagliflozin or matching placebo. The tablets will be identical in appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>effect of Empagliflozin 10mg qd versus placebo on cardiac output in patients with acute heart failure</measure>
    <time_frame>30 days</time_frame>
    <description>by ClearSight System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>30 days</time_frame>
    <description>Systemic vascular resistance (mmHg⋅min⋅mL-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>30 days</time_frame>
    <description>Stroke volume (ml/beat)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>30 days</time_frame>
    <description>Hand grip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio vascular</measure>
    <time_frame>30 days</time_frame>
    <description>blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Empagliflozin on systemic quality of life</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Empagliflozin on hospitalization due to cardiovascular causes or readmission for heart failure or renal failure</measure>
    <time_frame>30 days</time_frame>
    <description>length of initial hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Empagliflozin on death due to cardiovascular causes</measure>
    <time_frame>30 days</time_frame>
    <description>days alive and out of hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine</measure>
    <time_frame>30 days</time_frame>
    <description>24 h sodium excretion (mmol/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>30 days</time_frame>
    <description>body weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio vascular</measure>
    <time_frame>30 days</time_frame>
    <description>24 h heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>NT-proBNP (ng/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>cystatin C(mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>serum levels of Glucose, Glucagon, Insulin, Total-Ketone bodies, Hydroxybutyrate, Aldosterone, Free fatty acidy (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>Hemoglobin, Haematocrit, Erythropoietin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>30 days</time_frame>
    <description>breaths/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic response</measure>
    <time_frame>30 days</time_frame>
    <description>Δ weight kg/[(total i.v. dose)/40mg]+[(total oral dose)/80mg)] furosemide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney injury risk score</measure>
    <time_frame>30 days</time_frame>
    <description>by NephroCheck® (defined by TIMP-2 x IGFBP7 in urine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of microbiome</measure>
    <time_frame>30 days</time_frame>
    <description>stool sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported dyspnea</measure>
    <time_frame>30 days</time_frame>
    <description>visual analogue scale (VAS), 7 point categorical Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak expiratory flow rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen</measure>
    <time_frame>30 days</time_frame>
    <description>Saturation (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen</measure>
    <time_frame>30 days</time_frame>
    <description>delivered (l/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical judged diuretic requirement</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>Lactate, pH, HCO3-</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>30 days</time_frame>
    <description>Serum osmolarity, Potassium, Chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effecr of Empagliflozin 10 mg daily on Left ventricular systolic function</measure>
    <time_frame>30 days</time_frame>
    <description>ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effecr of Empagliflozin 10 mg daily on Left ventricular diastolic function</measure>
    <time_frame>30 days</time_frame>
    <description>2D and 3D parameter global strain rate E by echocardiography and by standardized parameter E/E' and left atrial (LA) volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive empagliflozin 10 mg qd for a period of 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Standard of Care + Empagliflozin: 10 mg (tablets) once daily</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Standard of Care + Placebo: Matching Placebo (tablets) once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Patients with acute heart failure with associated signs or symptoms (dyspnea on&#xD;
             exertion, orthopnea, paroxysmal dyspnea, peripheral oedema, chest x-ray with pulmonary&#xD;
             congestion)&#xD;
&#xD;
          3. Serum levels of NT-proBNP ≥ 1000 pg/ml within 48 hours of Informed Consent&#xD;
&#xD;
          4. Written informed consent prior to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes&#xD;
&#xD;
          2. Participants of child-bearing age without adequate contraception&#xD;
&#xD;
          3. Pregnancy or lactating females&#xD;
&#xD;
          4. Cardiogenic shock&#xD;
&#xD;
          5. Acute coronary syndrome within 30 days prior to randomization&#xD;
&#xD;
          6. Planned or recent percutaneous or surgical coronary intervention within 30 days prior&#xD;
             to randomization&#xD;
&#xD;
          7. Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH ≤ 7.30 and&#xD;
             glucose &gt;14 mmol/l and HCO3- ≤ 18 mmol/l)&#xD;
&#xD;
          8. Signs of uncontrolled active infection&#xD;
&#xD;
          9. Dyspnea due to non-cardiac causes (severe pulmonary disease, anemia, severe obesity),&#xD;
             non-HF causes such as acute or chronic respiratory disorders&#xD;
&#xD;
         10. Coronary artery disease with requirement for revascularization within the study period&#xD;
&#xD;
         11. Renal impairment (GFR &lt; 20 ml/min/1,73 m2)&#xD;
&#xD;
         12. Known hepatic impairment (as evidenced by total bilirubin &gt;3 mg/dL) or history of&#xD;
             cirrhosis with evidence of portal hypertension (e.g., presence of esophageal varices)&#xD;
&#xD;
         13. Uncontrolled thyroid disease&#xD;
&#xD;
         14. Endocrinopathies like Graves' disease, acromegaly, Cushings' disease&#xD;
&#xD;
         15. Hypertensive retinopathy or encephalopathy&#xD;
&#xD;
         16. Bariatric surgery in last 2 years prior to randomization&#xD;
&#xD;
         17. Patients in whom study participation is not deemed appropriate under consideration of&#xD;
             clinical wellbeing by the principal investigator&#xD;
&#xD;
         18. The subject is mentally or legally incapacitated&#xD;
&#xD;
         19. The subject received an investigational drug within 30 days prior to inclusion into&#xD;
             this study&#xD;
&#xD;
         20. Urinary tract infections or significant formation of residual urine in medical history&#xD;
&#xD;
         21. Patients with particular risk for ketoacidosis (alcohol abuse, pancreatitis,&#xD;
             pancreatic insulin deficiency from any cause, caloric restriction etc.) or&#xD;
             ketoacidosis in the past&#xD;
&#xD;
         22. Frequent hypoglycaemic events (in the opinion of the investigator)&#xD;
&#xD;
         23. Intolerance to Empagliflozin and excipients in Empagliflozin or rather placebo&#xD;
&#xD;
         24. Patients with severe stenosis or regurgitation of the aortic, pulmonary or mitral&#xD;
             valve&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Internal Medicine I RWTH Aachen University Hospital</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Empagliflozin</keyword>
  <keyword>acute heart failure</keyword>
  <keyword>cardiac output</keyword>
  <keyword>left ventricular systolic and diastolic function</keyword>
  <keyword>exercise capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

